Edaravone, a free radical scavenger, accelerates wound healing in diabetic mice.
Refractory wound healing is a major complication of diabetes, which restricts wound healing by interfering with the inflammatory response, decreasing granulation, causing peripheral neuropathy, and inhibiting angiogenesis. Oxidative stress has been proposed as an important pathogenic factor in diabetic wound complications. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a strong free radical scavenger that suppresses the effect of oxidative stress. Streptozotocin-induced diabetes was established in adult C57BL/6 mice, and full-thickness skin was then removed from the dorsomedial back using an 8-mm biopsy punch. Edaravone or vehicle alone was applied to the wound on day 0 and day 4 after wound creation. The wound was monitored with a digital camera and analyzed on days 0, 4, and 7 after wound creation. This study investigated whether accelerated wound closure occurred in the edaravone group (n = 24) compared with the vehicle-alone group (n = 15). On day 7, wound closure between the 2 groups was statistically different (P = 0.0019). Angiogenesis and lymphangiogenesis were markedly promoted. The possibility of an inhibitory effect of edaravone characterized by suppression of oxidative stress was explored. Edaravone-induced upregulation of endothelial nitric oxide synthase (eNOS) mRNA expression, and eNOS protein was immunohistochemically detected. Edaravone upregulates eNOS expression and accelerates wound healing.